top of page
lorlatinib_banner.jpg

Home / Information / Lorlatinib

Lorlatinib

Lorlatinib is a 3rd generation TKI developed by Pfizer. The recommended dose is 100mg taken daily.

​

Currently, Lorlatinib has been approved by the NHS for use after Alectinib and Brigatinib in the UK.  It has been approved by the Scottish Medicines Consortium for 1st line use in Scotland.

Documents

Name

Summary of Contents

Action

Crown Study 5-year Outcomes

This report contains information on the effectiveness of Lorlatinib for 1st line use.

Download

Lorlatinib For 2nd Line and Beyond

A report on Lorlatinib for 2nd line use.

Download

Management of Side Effects

A guide for health care professionals on the management of adverse effects arising from Lorlatinib.

Download

Lorlatinib Side Effects

This image shows the Lorlatinib side effects in a table format.

Download

Lorlatinib What to Expect (Pfizer)

A booklet from Pfizer on the side effects that patients may experience.

Download

Image
Image

ALK Positive Lung Cancer (UK) is committed to producing reliable, accurate and up-to-date content reflecting the best available research evidence and best clinical practice. We aim to provide unbiased information free from any commercial conflicts of interest.

​

ALK Positive Lung Cancer (UK) is a registered charity in England and Wales ((1181171) and Scotland (SC053692).  The registered office is at 1 Ethley Drive, Raglan, Monmouthshire, NP15 2FD.

The content of this website is for information only and should not be used for the diagnosis or treatment of medical conditions.  We are unable to offer specific medical advice and, if you are worried about any symptoms, you should consult your doctor.​​

View our privacy policy HERE        View our consent policy HERE

No part of this publication may be reproduced or tansmitted in any form or by any means, electronically, mechanically or manually without permission in writing of ALK Positive Lung Cancer (UK).

bottom of page